ADVERTISEMENT
Cohance Lifesciences Q4 Results Review: ICICI Securities Maintains 'Buy', Revises Target Price
Growth drivers across verticals in place for Cohance Lifesciences, says ICICI Securities
29 May 2025, 02:25 PM IST 
Cohance Lifesciences' pharma CDMO business could benefit from the commercialisation of one new molecule, while a recovery in specialty chemical segment may continue in FY26.(Photo source: Freepik)
Suven Pharma’s merger (all stock deal) with Cohance Lifesciences was effective from May 01, 2025 post which on May 19, 2025 the company was renamed to Cohance Lifesciences. The Q4 and FY25 proforma revenue includes revenue of Suven, Cohance, Sapala (67.5% stake acquired on 12th July 2024) and NJ Bio (56% stake acquired on 20th Dec 2024).
